FY23 facilities to f
Ended Awarded Last action
- Contract number
- 75N91023F00013
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,784,462
Award facts
- Contract value 100% obligated
- $1,784,462.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$45,853 | |
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,830,315 |
About this award
The National Cancer Institute (NCI) awarded a delivery order contract to Leidos Biomedical Research Inc., a Federally Funded Research and Development Center (FFRDC) contractor and subsidiary of Leidos Holdings, Inc., on September 27, 2023. This cost-plus-fixed-fee delivery order, valued at $1.78 million with an ultimate completion date of October 7, 2025, supports facilities and cost efficiency initiatives aligned with the President's Department of Government Efficiency objectives announced in March 2025. The contract was awarded without a set-aside designation, reflecting the contractor's competitive capabilities as an established FFRDC provider. Work is being performed at the contractor's location in Frederick, Maryland, where Leidos Biomedical Research Inc. maintains significant infrastructure supporting NCI and broader National Institutes of Health research operations.
Leidos Biomedical Research Inc. brings extensive experience delivering comprehensive biomedical research and facilities support services to federal agencies, including specialized capabilities in medical research, clinical trials, facility management, and advanced scientific solutions. The company's track record encompasses diverse projects such as cancer research, vaccine development, gene therapy development, infectious disease research, and clinical trial support. As a cost-plus-fixed-fee delivery order, this award represents a continuation of the contractor's ongoing relationship with NCI, leveraging its established expertise to optimize government facilities and operational efficiency consistent with current federal cost management initiatives.
Quick answers
Who was awarded contract 75N91023F00013?
75N91023F00013 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 27, 2023.
How much is contract 75N91023F00013 worth?
The government has obligated $1,784,462 on 75N91023F00013.
Is contract 75N91023F00013 an order under another contract?
Yes. 75N91023F00013 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00013 competed?
The extent of competition for 75N91023F00013 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award